Stephens Remains a Buy on Tenet Healthcare (THC)
In a report released today, from Stephens maintained a Buy rating on Tenet Healthcare, with a price target of $260.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
In a report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $242.00 price target.
Based on Tenet Healthcare’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $5.37 billion and a net profit of $702 million. In comparison, last year the company earned a revenue of $5.22 billion and had a net profit of $406 million
Based on the recent corporate insider activity of 58 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of THC in relation to earlier this year. Most recently, in March 2026, Paola M Arbour, the EVP & CIO of THC sold 6,500.00 shares for a total of $1,549,795.00.
Read More on THC:
Disclaimer & DisclosureReport an Issue
- Buy Rating Reiterated on Tenet Healthcare as Strong Q1 Execution Supports Upside; $242 Price Target Maintained
- Tenet Healthcare price target lowered to $254 from $260 at Morgan Stanley
- Tenet Healthcare selloff overdone, compelling longer term, says Cantor
- Tenet Healthcare price target lowered to $225 from $250 at KeyBanc
- Tenet Healthcare price target lowered to $252 from $283 at Guggenheim
